Skip to content


You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

  • Maggie J Rathos1,
  • Harshal Khanwalkar1,
  • Kavita Joshi1,
  • Sonal M Manohar1 and
  • Kalpana S Joshi2Email author
BMC Cancer201313:29

Received: 13 September 2012

Accepted: 16 January 2013

Published: 23 January 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting

Original Submission
13 Sep 2012 Submitted Original manuscript
17 Dec 2012 Author responded Author comments - kalpana joshi
Resubmission - Version 2
17 Dec 2012 Submitted Manuscript version 2
16 Jan 2013 Editorially accepted
23 Jan 2013 Article published 10.1186/1471-2407-13-29

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

Oncology Franchise, Piramal Healthcare Limited
Target Identification Group, Piramal Healthcare Limited